The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Tumor-Infiltrating FOXP3 + T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer
Abstract
Purpose: To determine the prognostic significance of FOXP3 + lymphocyte (Treg) density in colorectal cancer compared with conventional histopathologic features and with CD8 + and CD45RO + lymphocyte densities. Patients and Methods: Tissue microarrays and immunohistochemistry were used to assess the densities of CD8 + , CD45RO + , and FOXP3 + lymphocytes in tumor tissue and normal colonic mucosa from 967 stage II and stage III colorectal cancers. These were evaluated for associations with histopathologic features and patient survival. Results: FOXP3 + Treg density was higher in tumor tissue compared with normal colonic mucosa, whereas CD8 + and CD45RO + cell densities were lower. FOXP3 + Tregs were not associated with any histopathologic features, with the exception of tumor stage. Multivariate analysis showed that stage, vascular invasion, and FOXP3 + Treg density in normal and tumor tissue were independent prognostic indicators, but not CD8 + and CD45RO + . High FOXP3 + Treg density in normal mucosa was associated with worse prognosis (hazard ratio [HR] = 1.51; 95% CI, 1.07 to 2.13; P = .019). In contrast, a high density of FOXP3 + Tregs in tumor tissue was associated with improved survival (HR = 0.54; 95% CI, 0.38 to 0.77; P = .001). Conclusion: FOXP3 + Treg density in normal and tumor tissue had stronger prognostic significance in colorectal cancer compared with CD8 + and CD45RO + lymphocytes. The finding of improved survival associated with a high density of tumor-infiltrating FOXP3 + Tregs in colorectal cancer contrasts with several other solid cancer types. The inclusion of FOXP3 + Treg density may help to improve the prognostication of early-stage colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745 · cited 2×
“The most specific Treg cell marker identified to date is the nuclear transcription factor known as FOXP3.(20,21) A high density of tumor-infiltrating FOXP3 Tregs has been associated with poor outcome in various solid tumors, including ovarian,(22,23) pancreatic,(24) and hepatocellular carcinoma.”
BackgroundType, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135 · cited 4×
“The better prognosis associated with high densities of CD8 T and CD45RO T (Table 4) agrees with earlier studies.(12,15) High densities of these cells have been linked to the suppression of metastasis.”
BackgroundResultInfluentialRegulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
Bates, G. J., Fox, S. B., Han, C., Leek, R. D., Garcia, J. F., Harris, A. L., & Banham, A. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9584 · Cited by 1,200
CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.
Naito, Y., Saito, K., Shiiba, K., Ohuchi, A., Saigenji, K., Nagura, H., & Ohtani, H. (1998) · PubMed · Cited by 1,193
Gao, Q., Qiu, S.-J., Fan, J., Zhou, J., Wang, X.-Y., Xiao, Y.-S., Xu, Y., Li, Y.-W., & Tang, Z.-Y. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4565 · Cited by 1,110
Cited by
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Natural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101
Regulatory T cells in cancer immunotherapy
Tanaka, A., & Sakaguchi, S. (2017) · Cell Research · doi:10.1038/cr.2016.151 · Cited by 1,860
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Bruni, D., Angell, H. K., & Galon, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0285-7 · Cited by 1,586
Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours
Galon, J., Mlecnik, B., Bindea, G., Angell, H. K., Berger, A., Lagorce, C., Lugli, A., Zlobec, I., Hartmann, A., Bifulco, C., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4287 · Cited by 1,360
Tosolini, M., Kirilovsky, A., Mlecnik, B., Fredriksen, T., Mauger, S., Bindea, G., Berger, A., Bruneval, P., Fridman, W.-H., Pagès, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2907 · Cited by 1,146
Regulatory T Cells and Human Disease
Sakaguchi, S., Mikami, N., Wing, J. B., Tanaka, A., Ichiyama, K., & Ohkura, N. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041717 · Cited by 1,120
Immune infiltration in human tumors: a prognostic factor that should not be ignored
Pagès, F., Galon, J., Dieu-Nosjean, M.-C., Tartour, E., Sautès-Fridman, C., & Fridman, W.-H. (2010) · Oncogene · doi:10.1038/onc.2009.416 · Cited by 1,087
Shang, B., Liu, Y., Jiang, S.-J., & Liu, Y. (2015) · Scientific Reports · doi:10.1038/srep15179 · Cited by 985
Denkert, C., von Minckwitz, G., Brase, J. C., Sinn, B. V., Gade, S., Kronenwett, R., Pfitzner, B. M., Salat, C., Loi, S., Schmitt, W. D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1967 · Cited by 1,026
Merlos-Suárez, A., Barriga, F. M., Jung, P., Iglesias, M., Céspedes, M. V., Rossell, D., Sevillano, M., Hernando-Momblona, X., da Silva-Diz, V., Muñoz, P., et al. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.02.020 · Cited by 934
“, 2005) and FOXP3 (Frey et al., 2009; Salama et al., 2009).”
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Schwartzentruber, D. J., Lawson, D. H., Richards, J. M., Conry, R. M., Miller, D. M., Treisman, J., Gailani, F., Riley, L., Conlon, K., Pockaj, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012863 · Cited by 911
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016) · Nature Medicine · doi:10.1038/nm.4086 · Cited by 871
Obesity, Inflammation, and Cancer
Deng, T., Lyon, C. J., Bergin, S., Caligiuri, M. A., & Hsueh, W. A. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044359 · Cited by 794
Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer
Wing, J. B., Tanaka, A., & Sakaguchi, S. (2019) · Immunity · doi:10.1016/j.immuni.2019.01.020 · Cited by 726
Regulatory T cells in cancer immunotherapy
Nishikawa, H., & Sakaguchi, S. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.12.005 · Cited by 705
Fusobacterium nucleatum and T Cells in Colorectal Carcinoma
Mima, K., Sukawa, Y., Nishihara, R., Qian, Z. R., Yamauchi, M., Inamura, K., Kim, S. A., Masuda, A., Nowak, J. A., Nosho, K., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1377 · Cited by 669
Badoual, C., Hans, S., Merillon, N., Van Ryswick, C., Ravel, P., Benhamouda, N., Levionnois, E., Nizard, M., Si-Mohamed, A., Besnier, N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2606 · Cited by 633
Angell, H., & Galon, J. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.03.004 · Cited by 574
CD4 and CD8 T lymphocyte interplay in controlling tumor growth
Ostroumov, D., Fekete-Drimusz, N., Saborowski, M., Kühnel, F., & Woller, N. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2686-7 · Cited by 549
Picard, E., Verschoor, C. P., Ma, G. W., & Pawelec, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00369 · Cited by 522
Chaudhary, B., & Elkord, E. (2016) · Vaccines · doi:10.3390/vaccines4030028 · Cited by 511
Nosho, K., Baba, Y., Tanaka, N., Shima, K., Hayashi, M., Meyerhardt, J. A., Giovannucci, E., Dranoff, G., Fuchs, C. S., & Ogino, S. (2010) · The Journal of Pathology · doi:10.1002/path.2774 · Cited by 502
Disis, M. L. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2146 · Cited by 489
Szajnik, M., Czystowska, M., Szczepanski, M. J., Mandapathil, M., & Whiteside, T. L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011469 · Cited by 462
Milne, K., Köbel, M., Kalloger, S. E., Barnes, R. O., Gao, D., Gilks, C. B., Watson, P. H., & Nelson, B. H. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006412 · Cited by 446
Tumor-Infiltrating Dendritic Cells in Cancer Pathogenesis
Tran Janco, J. M., Lamichhane, P., Karyampudi, L., & Knutson, K. L. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1403134 · Cited by 440
deLeeuw, R. J., Kost, S. E., Kakal, J. A., & Nelson, B. H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3216 · Cited by 437
Clinical impact of programmed cell death ligand 1 expression in colorectal cancer
Droeser, R. A., Hirt, C., Viehl, C. T., Frey, D. M., Nebiker, C., Huber, X., Zlobec, I., Eppenberger-Castori, S., Tzankov, A., Rosso, R., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.02.015 · Cited by 431
Cancer immunotherapy – revisited
Lesterhuis, W. J., Haanen, J. B. A. G., & Punt, C. J. A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3500 · Cited by 427
Halama, N., Michel, S., Kloor, M., Zoernig, I., Benner, A., Spille, A., Pommerencke, T., von Knebel, D. M., Folprecht, G., Luber, B., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0268 · Cited by 420
Ogino, S., Nosho, K., Irahara, N., Meyerhardt, J. A., Baba, Y., Shima, K., Glickman, J. N., Ferrone, C. R., Mino-Kenudson, M., Tanaka, N., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1438 · Cited by 418
(2010) · Advances in Cancer Research · doi:10.1016/s0065-230x(10)07003-x · Cited by 386
Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma
Nguyen, N., Bellile, E., Thomas, D., McHugh, J., Rozek, L., Virani, S., Peterson, L., Carey, T. E., Walline, H., Moyer, J., et al. (2016) · Head & Neck · doi:10.1002/hed.24406 · Cited by 353
Jochems, C., & Schlom, J. (2011) · Experimental Biology and Medicine · doi:10.1258/ebm.2011.011007 · Cited by 353
FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets
Saleh, R., & Elkord, E. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.022 · Cited by 352
Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer
Nosho, K. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i2.557 · Cited by 344
The development and function of regulatory T cells
Workman, C. J., Szymczak-Workman, A. L., Collison, L. W., Pillai, M. R., & Vignali, D. A. A. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0026-2 · Cited by 344
Frey, D. M., Droeser, R. A., Viehl, C. T., Zlobec, I., Lugli, A., Zingg, U., Oertli, D., Kettelhack, C., Terracciano, L., & Tornillo, L. (2010) · International Journal of Cancer · doi:10.1002/ijc.24989 · Cited by 333
Tumor-Infiltrating Immune Cells Act as a Marker for Prognosis in Colorectal Cancer
Ye, L., Zhang, T., Kang, Z., Guo, G., Sun, Y., Lin, K., Huang, Q., Shi, X., Ni, Z., Ding, N., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02368 · Cited by 332
Ladoire, S., Martin, F., & Ghiringhelli, F. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1046-y · Cited by 331
Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer
Erreni, M., Mantovani, A., & Allavena, P. (2011) · Cancer Microenvironment · doi:10.1007/s12307-010-0052-5 · Cited by 325
Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
Riera-Domingo, C., Audigé, A., Granja, S., Cheng, W.-C., Ho, P.-C., Baltazar, F., Stockmann, C., & Mazzone, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00018.2019 · Cited by 310
Sacdalan, D. B., Lucero, J. A., & Sacdalan, D. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s153290 · Cited by 306
Mei, Z., Liu, Y., Liu, C., Cui, A., Liang, Z., Wang, G., Peng, H., Cui, L., & Li, C. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.46 · Cited by 305
Liu, F., Lang, R., Zhao, J., Zhang, X., Pringle, G. A., Fan, Y., Yin, D., Gu, F., Yao, Z., & Fu, L. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1647-3 · Cited by 301
Immune checkpoint inhibitors in cancer therapy: a focus on T‐regulatory cells
Sasidharan Nair, V., & Elkord, E. (2018) · Immunology & Cell Biology · doi:10.1111/imcb.1003 · Cited by 298
Current status of interleukin-10 and regulatory T-cells in cancer
Dennis, K. L., Blatner, N. R., Gounari, F., & Khazaie, K. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000006 · Cited by 289
What are regulatory T cells (Treg) regulating in cancer and why?
Whiteside, T. L. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.03.004 · Cited by 291
Idos, G. E., Kwok, J., Bonthala, N., Kysh, L., Gruber, S. B., & Qu, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-60255-4 · Cited by 291
Microsatellite instability in colorectal cancer
IACOPETTA, B., GRIEU, F., & AMANUEL, B. (2010) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2010.01335.x · Cited by 289
Self-citationCancer immunology—analysis of host and tumor factors for personalized medicine
Ogino, S., Galon, J., Fuchs, C. S., & Dranoff, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.122 · Cited by 284
Gut microbiota modulate T cell trafficking into human colorectal cancer
Cremonesi, E., Governa, V., Garzon, J. F. G., Mele, V., Amicarella, F., Muraro, M. G., Trella, E., Galati-Fournier, V., Oertli, D., Däster, S. R., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313498 · Cited by 275
Li, Y., Liang, L., Dai, W., Cai, G., Xu, Y., Li, X., Li, Q., & Cai, S. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0539-x · Cited by 270
West, N. R., Kost, S. E., Martin, S. D., Milne, K., deLeeuw, R. J., Nelson, B. H., & Watson, P. H. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.524 · Cited by 268
Shah, W., Yan, X., Jing, L., Zhou, Y., Chen, H., & Wang, Y. (2011) · Cellular & Molecular Immunology · doi:10.1038/cmi.2010.56 · Cited by 267
Limagne, E., Euvrard, R., Thibaudin, M., Rébé, C., Derangère, V., Chevriaux, A., Boidot, R., Végran, F., Bonnefoy, N., Vincent, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3164 · Cited by 264
Emerging Functions of Regulatory T Cells in Tissue Homeostasis
Sharma, A., & Rudra, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00883 · Cited by 262
Immune Infiltration in Human Cancer: Prognostic Significance and Disease Control
Fridman, W. H., Galon, J., Dieu-Nosjean, M.-C., Cremer, I., Fisson, S., Damotte, D., Pagès, F., Tartour, E., & Sautès-Fridman, C. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_46 · Cited by 258
Epigenetics and Colorectal Cancer Pathogenesis
Bardhan, K., & Liu, K. (2013) · Cancers · doi:10.3390/cancers5020676 · Cited by 252
Shimizu, K., Nakata, M., Hirami, Y., Yukawa, T., Maeda, A., & Tanemoto, K. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181d60fd7 · Cited by 244
Barua, S., Fang, P., Sharma, A., Fujimoto, J., Wistuba, I., Rao, A. U. K., & Lin, S. H. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.01.022 · Cited by 223
Keung, E. Z., Burgess, M., Salazar, R., Parra, E. R., Rodrigues-Canales, J., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Attia, S., Riedel, R. F., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1824 · Cited by 215
Roberti, M. P., Yonekura, S., Duong, C. P. M., Picard, M., Ferrere, G., Tidjani Alou, M., Rauber, C., Iebba, V., Lehmann, C. H. K., Amon, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0882-8 · Cited by 208
Immune system: a double-edged sword in cancer
Lakshmi Narendra, B., Eshvendar Reddy, K., Shantikumar, S., & Ramakrishna, S. (2013) · Inflammation Research · doi:10.1007/s00011-013-0645-9 · Cited by 206
Dual role of tumour-infiltrating T helper 17 cells in human colorectal cancer
Amicarella, F., Muraro, M. G., Hirt, C., Cremonesi, E., Padovan, E., Mele, V, Governa, V, Han, J., Huber, X., Droeser, R. A., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-310016 · Cited by 189
Probiotic Microbes Sustain Youthful Serum Testosterone Levels and Testicular Size in Aging Mice
Poutahidis, T., Springer, A., Levkovich, T., Qi, P., Varian, B. J., Lakritz, J. R., Ibrahim, Y. M., Chatzigiagkos, A., Alm, E. J., & Erdman, S. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084877 · Cited by 177
Microbial Reprogramming Inhibits Western Diet-Associated Obesity
Poutahidis, T., Kleinewietfeld, M., Smillie, C., Levkovich, T., Perrotta, A., Bhela, S., Varian, B. J., Ibrahim, Y. M., Lakritz, J. R., Kearney, S. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068596 · Cited by 164
Haas, M., Dimmler, A., Hohenberger, W., Grabenbauer, G. G., Niedobitek, G., & Distel, L. V. (2009) · BMC Gastroenterology · doi:10.1186/1471-230x-9-65 · Cited by 154
Tanchot, C., Terme, M., Pere, H., Tran, T., Benhamouda, N., Strioga, M., Banissi, C., Galluzzi, L., Kroemer, G., & Tartour, E. (2013) · Cancer Microenvironment · doi:10.1007/s12307-012-0122-y · Cited by 138
Colorectal cancer and immunity: What we know and perspectives
Pernot, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i14.3738 · Cited by 131
Guo, L., Wang, C., Qiu, X., Pu, X., & Chang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01052 · Cited by 122
Kumar, P., Saini, S., & Prabhakar, B. S. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.01.006 · Cited by 117
Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity
Yano, H., Andrews, L. P., Workman, C. J., & Vignali, D. A. A. (2019) · Immunology · doi:10.1111/imm.13067 · Cited by 116
Bishehsari, F., Engen, P. A., Voigt, R. M., Swanson, G., Shaikh, M., Wilber, S., Naqib, A., Green, S. J., Shetuni, B., Forsyth, C. B., et al. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.10.011 · Cited by 76
“High FOXP3þ and low RORgtþ cell densities within tumors are associated with improved survival of CRC patients.(37,38,52,53) The Cancer Genome Atlas analysis confirmed the inverse correlation between FOXP3 and RORC expression in human CRC.”
BackgroundEcharti, A., Hecht, M., Büttner-Herold, M., Haderlein, M., Hartmann, A., Fietkau, R., & Distel, L. (2019) · Cancers · doi:10.3390/cancers11091398 · Cited by 87
Williams, D. S., Mouradov, D., Jorissen, R. N., Newman, M. R., Amini, E., Nickless, D. K., Teague, J. A., Fang, C. G., Palmieri, M., Parsons, M. J., et al. (2019) · Gut · doi:10.1136/gutjnl-2017-315664 · Cited by 79
Berntsson, J., Eberhard, J., Nodin, B., Leandersson, K., Larsson, A. H., & Jirström, K. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1465165 · Cited by 62
Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice
Ragusa, S., Prat-Luri, B., González-Loyola, A., Nassiri, S., Squadrito, M. L., Guichard, A., Cavin, S., Gjorevski, N., Barras, D., Marra, G., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129558 · Cited by 56
“The role of Tregs in human CRC is controversial: high intratumoral Treg density has been associated with better outcomes (76, 77), whereas other data indicate that Tregs promote protumor Th17 responses and suppress tumor-specific CD8 + T cell activation in patients with CRC (78).”
Unraveling resistance to immunotherapy in MSI-high colorectal cancer
Heregger, R., Huemer, F., Steiner, M., Gonzalez-Martinez, A., Greil, R., & Weiss, L. (2023) · Cancers · doi:10.3390/cancers15205090 · Cited by 52
Foxo transcription factors in T cell biology and tumor immunity
Luo, C. T., & Li, M. O. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.04.006 · Cited by 46
“However, in some studies of colorectal and head and neck tumors, Foxp3+ T cell infiltration indicates better patient outcome [49, 50], which can be explained by the heterogeneity of Foxp3+ populations in human and the infiltration of Foxp3+ non-regulatory T subsets [51, 52].”
BackgroundEfferocytosis Creates a Tumor Microenvironment Supportive of Tumor Survival and Metastasis
(2015) · Cancer Cell & Microenvironment · doi:10.14800/ccm.666 · Cited by 44
Fantini, M. C., Favale, A., Onali, S., & Facciotti, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186744 · Cited by 40
Posselt, R., Erlenbach-Wünsch, K., Haas, M., Jeßberger, J., Büttner-Herold, M., Haderlein, M., Hecht, M., Hartmann, A., Fietkau, R., & Distel, L. V. (2016) · Oncotarget · doi:10.18632/oncotarget.11039 · Cited by 38
“com/oncotarget survival [14, 15] and overall survival [16] in colorectal cancer.”
BackgroundThe appearance of Tregs in cancer nest is a promising independent risk factor in colon cancer
Xu, W., Liu, H., Song, J., Fu, H.-X., Qiu, L., Zhang, B.-F., Li, H.-Z., Bai, J., & Zheng, J.-N. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1500-7 · Cited by 31
CD30+OX40+ Treg is associated with improved overall survival in colorectal cancer
Lam, J. H., Hong, M., Koo, S.-L., Chua, C. W. L., Lim, K. L., Wee, F., Wan, W. K., Leow, W. Q., Yeo, J. G., Tan, I. B. H., et al. (2021) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-021-02859-x · Cited by 31
Ma, Y., Nenkov, M., Chen, Y., & Gaßler, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158352 · Cited by 28
A Paradoxical Role for Regulatory T Cells in the Tumor Microenvironment of Pancreatic Cancer
Brouwer, T., Ijsselsteijn, M., Oosting, J., Ruano, D., van der Ploeg, M., Dijk, F., Bonsing, B., Fariña, A., Morreau, H., Vahrmeijer, A., et al. (2022) · Cancers · doi:10.3390/cancers14163862 · Cited by 24
Metadata
- Authors
- Salama, P., Phillips, M., Grieu, F., Morris, M., Zeps, N., Joseph, D., Platell, C., & Iacopetta, B.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-01-10
- Volume
- 27
- Issue
- 2
- Pages
- 186-192
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2128640763
- Cited by
- 991
- References
- 38
- FWCI
- 18.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.